- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07453290
Desregulación del Eje Soluble α-Klotho-FGF23 en la Tiroiditis de Hashimoto: Un Estudio de Casos y Controles (klofgfhashi)
El estudio KLASH: Desregulación del eje soluble α-Klotho-FGF23 en la tiroiditis de Hashimoto - Un estudio prospectivo de casos y controles
Hashimoto's thyroiditis (HT) is the most common autoimmune thyroid disease and is increasingly recognized as a condition associated with chronic low-grade systemic inflammation beyond thyroid hormone dysfunction. The soluble α-Klotho-fibroblast growth factor 23 (FGF23) axis plays a central role in mineral metabolism, inflammation, and aging-related pathways; however, its involvement in HT has not been adequately characterized.
This prospective case-control study aims to compare serum soluble α-Klotho and FGF23 levels between adults with Hashimoto's thyroiditis and age- and sex-matched healthy controls, and to investigate their associations with thyroid function parameters, inflammatory markers, and autoimmune burden. In addition, the FGF23/sKlotho ratio will be evaluated as an integrated marker of functional imbalance within the Klotho-FGF23 axis.
The study seeks to determine whether Hashimoto's thyroiditis is associated with systemic dysregulation of the Klotho-FGF23 pathway independent of renal function and mineral metabolism.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Hashimoto's thyroiditis (HT) is a chronic autoimmune disease characterized by lymphocytic infiltration of the thyroid gland and the presence of anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies. While traditionally defined by thyroid hormone dysfunction, emerging evidence suggests that HT is associated with persistent immune activation, oxidative stress, and low-grade systemic inflammation.
The α-Klotho-FGF23 axis is an endocrine pathway involved in phosphate metabolism, vitamin D regulation, inflammation, and aging-related biological processes. Soluble α-Klotho (sKlotho) exerts anti-inflammatory and anti-oxidative effects, whereas FGF23 is increasingly recognized as a hormone influenced by inflammatory stimuli. Dysregulation of this axis has been reported in various chronic inflammatory conditions; however, data in autoimmune thyroid disease are limited.
This prospective, single-center case-control study will include adult patients with Hashimoto's thyroiditis and healthy controls without thyroid or systemic autoimmune disease. Serum soluble α-Klotho and FGF23 levels will be measured using enzyme-linked immunosorbent assay (ELISA). Clinical data including thyroid function tests (TSH, free T4), thyroid autoantibodies (anti-TPO, anti-TG), renal function parameters, mineral metabolism markers (calcium, phosphorus, 25-hydroxyvitamin D), and C-reactive protein (CRP) will be recorded.
Primary analyses will compare sKlotho and FGF23 levels between groups. Secondary analyses will evaluate associations between these biomarkers and autoimmune burden (anti-TG levels), inflammatory status (CRP), and thyroid function. Multivariable regression models will be used to determine independent associations after adjustment for potential confounders.
The study also aims to evaluate the FGF23/sKlotho ratio as an integrated indicator of functional imbalance within the Klotho-FGF23 axis in Hashimoto's thyroiditis.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Istanbul, Turquía (Türkiye)
- Istanbul Kanuni Sultan Suleyman Training and Research Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adult participants aged 18-65 years will be recruited from the endocrinology outpatient clinic of a tertiary care center. The study population will consist of patients diagnosed with Hashimoto's thyroiditis and age- and sex-matched healthy controls without thyroid or systemic autoimmune disease. All participants will undergo baseline clinical evaluation and venous blood sampling for measurement of soluble α-Klotho and FGF23 levels, along with routine laboratory parameters.
Descripción
Inclusion Criteria:
- Adults aged 18-65 years
- Ability to provide written informed consent
- Hashimoto group: Diagnosis of Hashimoto's thyroiditis based on positive anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-TG) antibodies with compatible clinical/ultrasound findings, as available
- Control group: No history of thyroid disease or autoimmune disease; normal thyroid function tests (TSH and free T4 within the reference range)
Exclusion Criteria:
- Pregnancy or breastfeeding
- Known chronic kidney disease (eGFR <60 mL/min/1.73 m²)
- Active infection or acute inflammatory condition within the past 4 weeks
- Known malignancy under active treatment
- Chronic inflammatory/autoimmune disease other than Hashimoto's thyroiditis (e.g., rheumatoid arthritis, SLE, IBD)
- Use of systemic glucocorticoids or immunosuppressive therapy within the past 3 months
- Known parathyroid disease or disorders of calcium/phosphate metabolism
- Current use of medications strongly affecting mineral metabolism (e.g., phosphate binders, active vitamin D analogs)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_CONTROL
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Hashimoto Disease
Adults aged 18-65 years diagnosed with Hashimoto's thyroiditis based on clinical evaluation, thyroid function tests, and positive anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-TG) antibodies. Participants may be euthyroid or hypothyroid. Serum soluble α-Klotho and FGF23 levels will be measured. Clinical, inflammatory, renal, and mineral metabolism parameters will be recorded. |
Venous blood sampling for measurement of serum soluble α-Klotho and fibroblast growth factor 23 (FGF23) levels using enzyme-linked immunosorbent assay (ELISA). No therapeutic intervention is administered. |
|
Healthy Controls
Age- and sex-matched adults without a history of thyroid disease, autoimmune disorders, chronic kidney disease, or chronic systemic illness. Participants will have normal thyroid function tests. Serum soluble α-Klotho and FGF23 levels will be measured, and clinical laboratory parameters will be recorded for comparison. |
Venous blood sampling for measurement of serum soluble α-Klotho and fibroblast growth factor 23 (FGF23) levels using enzyme-linked immunosorbent assay (ELISA). No therapeutic intervention is administered. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Diferencia en los niveles séricos de α-Klotho soluble entre la tiroiditis de Hashimoto y los controles sanos
Periodo de tiempo: Baseline
|
Baseline
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: İrem Utku, Tekirdağ Doktor İsmail Fehmi Cumalıoğlu City Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades de la tiroides
- Tiroiditis
- Enfermedad de Hashimoto
- Tiroiditis Autoinmune
- Técnicas de investigación
- Manejo de muestras
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Puntas
- Procedimientos quirúrgicos, operativo
- Recolección de muestras de sangre
Otros números de identificación del estudio
- TKD-GER-2026-02
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .